Blood protein predictors of brain amyloid for enrichment in clinical trials?

Blood protein predictors of brain amyloid for enrichment in clinical trials?

Abstract Background Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood‐based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large‐scale prev...

Full description

Bibliographic Details
Main Authors: Nicholas J. Ashton, Steven J. Kiddle, John Graf, Malcolm Ward, Alison L. Baird, Abdul Hye, Sarah Westwood, Karyuan Vivian Wong, Richard J. Dobson, Gil D. Rabinovici, Bruce L. Miller, Howard J. Rosen, Andrew Torres, Zhanpan Zhang, Lennart Thurfjell, Antonia Covin, Cristina Tan Hehir, David Baker, Chantal Bazenet, Simon Lovestone, AIBL Research Group
Format: Article
Language:English
Published: Wiley 2015-03-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Plasma
β amyloid
Proteomics
Alzheimer's disease
Biomarker
Fibrinogen γ‐chain
Online Access:https://doi.org/10.1016/j.dadm.2014.11.005

Internet

https://doi.org/10.1016/j.dadm.2014.11.005

Similar Items